thiazoles has been researched along with Neuroendocrine Tumors in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aristizabal Prada, ET; Auernhammer, CJ; Grabowski, P; Grossman, A; Lauseker, M; Maurer, J; Nölting, S; Orth, M; Spöttl, G; Weis, C | 1 |
| Arnold, R; Bartsch, DK; Fendrich, V; Hörsch, D; Karhoff, D; Sauer, S; Schrader, J | 1 |
2 other study(ies) available for thiazoles and Neuroendocrine Tumors
| Article | Year |
|---|---|
GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Glycogen Synthase Kinase 3 beta; Humans; Neuroendocrine Tumors; Thiazoles; Urea | 2018 |
Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.
Topics: Benzenesulfonates; Digestive System Neoplasms; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; raf Kinases; rap1 GTP-Binding Proteins; Signal Transduction; Sorafenib; Tetrazolium Salts; Thiazoles | 2007 |